Literature DB >> 16753419

Cavectomy for the treatment of Wilms tumor with vascular extension.

Rodrigo Chaves Ribeiro1, Sergio Tomaz Schettini, Simone de Campos Vieira Abib, José Honório Palma da Fonseca, Mônica Cypriano, Nasjla Saba da Silva.   

Abstract

PURPOSE: Vascular extension to the vena cava occurs in 4% of Wilms tumor cases and can reach the right atrium in up to 1%. When this happens the thrombus is usually not adherent to the vessel wall, and there is blood flow around it. Preoperative chemotherapy can cause thrombus regression and even resolution. If the thrombus persists after chemotherapy, surgery will be a challenge. On the other hand, if the thrombus invades the vessel wall, its removal may not be feasible. In this situation cavectomy is a good surgical strategy because it provides complete resection. The prerequisite for cavectomy is the absence of blood flow in the vena cava on preoperative Doppler ultrasonography. We report 3 cases of Wilms tumor with vena caval invasion in which cavectomy was performed, and discuss the principles, indications and operative technique.
MATERIALS AND METHODS: A total of 171 patients with Wilms tumor were treated at our institution between 1984 and 2004. Of these patients 6 with intravascular extension of thrombus within the right atrium were treated with extracorporeal circulation, cardiac arrest and profound hypothermia, and 3 were treated with cavectomy.
RESULTS: There were no instances of surgical complications or postoperative renal failure in our patients who underwent cavectomy. All remain well and free of disease.
CONCLUSIONS: Cavectomy is a safe procedure for treating pediatric patients with Wilms tumor when there is extension and invasion of the vena cava wall without blood flow.

Entities:  

Mesh:

Year:  2006        PMID: 16753419     DOI: 10.1016/S0022-5347(06)00561-1

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  8 in total

1.  [Risk factors for intra- and postoperative complications in Wilms' tumor surgery].

Authors:  V Zugor; D Krot; G E Schott
Journal:  Urologe A       Date:  2007-03       Impact factor: 0.639

2.  International Society of Paediatric Surgical Oncology (IPSO) Surgical Practice Guidelines.

Authors:  Simone de Campos Vieira Abib; Chan Hon Chui; Sharon Cox; Abdelhafeez H Abdelhafeez; Israel Fernandez-Pineda; Ahmed Elgendy; Jonathan Karpelowsky; Pablo Lobos; Marc Wijnen; Jörg Fuchs; Andrea Hayes; Justin T Gerstle
Journal:  Ecancermedicalscience       Date:  2022-02-17

Review 3.  Wilms tumour: prognostic factors, staging, therapy and late effects.

Authors:  Sue C Kaste; Jeffrey S Dome; Paul S Babyn; Norbert M Graf; Paul Grundy; Jan Godzinski; Gill A Levitt; Helen Jenkinson
Journal:  Pediatr Radiol       Date:  2007-11-17

4.  Surgical management and outcomes of 12 cases of Wilms tumour with intracardiac extension from a single centre.

Authors:  Sharon G Cox; A Davidson; J Thomas; A Brooks; J Hewitson; A Numanoglu; A J W Millar
Journal:  Pediatr Surg Int       Date:  2017-10-11       Impact factor: 1.827

5.  Wilms tumor with intravascular tumor thrombus.

Authors:  Suna Emir
Journal:  Transl Pediatr       Date:  2014-01

6.  Adrenocortical carcinoma with extension to the inferior vena cava and right atrium: 20-month-old girl with TP53 mutation.

Authors:  Terry L Levin; Walter E Berdon; Daniel Weiser; Raul C Ribeiro
Journal:  Radiol Case Rep       Date:  2016-02-17

7.  Impact of neoadjuvant chemotherapy on thrombus viability in patients with Wilms tumour and caval extension: systematic review with meta-analysis.

Authors:  T D Boam; M Gabriel; R Shukla; P D Losty
Journal:  BJS Open       Date:  2021-05-07

8.  Management of Pediatric Tumors With Vascular Extension.

Authors:  Mayara Caroline Amorim Fanelli; José Cícero Stocco Guilhen; Alexandre Alberto Barros Duarte; Fernanda Kelly Marques de Souza; Monica Dos Santos Cypriano; Eliana Maria Monteiro Caran; Henrique Manoel Lederman; Maria Teresa de Seixas Alves; Simone de Campos Vieira Abib
Journal:  Front Pediatr       Date:  2022-01-04       Impact factor: 3.418

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.